Table 2.

Clinical Characteristics and Recovery Duration of Our Reviewed Patients. The Recovery Day of Thrombocytopenia in Case 11 Is Described as “NA” (*) because the Platelet Count Remained above 10×10⁴/μL throughout the Entire Hospitalization Period. These Data are Not Included in the Analysis.

	Case	Race	Age/ Sex	TAFRO grade	Critical complications before remission	Infections	Treatment	CRP <1.0mg/dL (day)	AKI improved (day)	PLT >105 /L (day)	Reference
without critical complications	1	Japanese	51 F	2	None	NA	mPSL pulse, PSL	20	10	40	6
	2	Japanese	38 M	3	None	NA	mPSL pulse, PSL, CsA, TCZ	15	33	38	7
	3	Japanese	85 F	3	None	NA	PSL	12	15	40	8
	4	Japanese	76 F	4	None	NA	PSL	32	49	70	9
	5	Japanese	46 M	4	None	NA	mPSL pulse, PSL, TCZ	25	34	36	10
	6	Chinese	52 F	4	None	Pneumonia before remission (unknown etiology)	mPSL, PSL, BOR, CPA, DEX	25	20	44	11
	7	Japanese	69 M	4	None	CMV, cholecystitis after remission (unknown etiology), Mycobacterium tuberculosis after remission	mPSL pulse, PSL, CsA	40	45	175	12
	8	Japanese	48 F	4	None	NA	mPSL pulse, PSL, TCZ, CsA	20	21	51	13
	9	Japanese	60 M	5	None	CMV, BK virus	mPSL pulse, PSL, TCZ, CsA	18	39	169	Our case
with critical complications	10	Japanese	68 F	2	Septic shock	Staphylococcus aureus	PSL, TCZ, CsA, TAC	131	221	120	14
	11	Japanese	17 M	3	Cardiogenic shock	NA	mPSL pulse, PSL, TAC	6	3	NA	14
	12	Japanese	72 M	5	Cardiac arrest	Corynebacterium	mPSL pulse, PSL, TCA, CPA	28	120	140	15
	13	Japanese	59 M	5	Cardiac arrest	NA	mPSL pulse, PSL, TCZ, CsA	23	37	88	16
	14	Japanese	25 M	5	Cardiac arrest	NA	PSL, CPA, TCZ	49	76	75	17
	15	Japanese	59 M	5	Hemorrhagic shock	Pneumocystis jirovecii, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Clostridium difficile, Escherichia coli, CMV, Candida	mPSL pulse, PSL, TCZ	166	228	215	18

AKI: acute kidney injury, PLT: platelet, CMV: cytomegalovirus, mPSL: methyl prednisolone, PSL: prednisolone, CsA: ciclosporin, TCZ: tocilizumab, BOR: bortezomib, CPA: cyclophosphamide, DEX: dexamethasone